Ekaterina Proskuriakova, Dhan Bahadur Shrestha, Ranjit Jasaraj, Vijay Ketan Reddy, Jurgen Shtembari, Anuradha Raut, Suman Gaire, Paramjeet Khosla, Dinesh Kadariya
PURPOSE: Cardiovascular adverse events (CVAEs) are common adverse effects of first-generation Bruton tyrosine kinase inhibitors (BTKis) and limit their use considerably. This led to the development of second-generation BTKis-acalabrutinib and zanubrutinib-which are more selective, potent, and presumed to have better safety profiles than the previous group of medications. However, there have been sporadic reports of CVAEs associated with second-generation BTKis in clinical practice. To address this issue, a comprehensive meta-analysis to pool the documented CVAEs was performed, including major hemorrhage, any bleeding, atrioventricular block, atrial fibrillation/flutter, pericardial effusion, pericarditis, heart failure, cardiac arrest, myocardial infarction, hypertension, hypotension, and stroke...
December 14, 2023: Clinical Therapeutics